News | December 26, 2023
AstraZeneca to acquire China's Gracell Biotechnologies for US $1.2 billion
Furthering cell therapy ambition across oncology and autoimmune diseases
Furthering cell therapy ambition across oncology and autoimmune diseases
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Expanding to states like Maharashtra, Andhra Pradesh, Telangana, and Manipur while marking the significant milestone in its journey towards providing accessible healthcare services
Increased capability to produce medicines for challenging diseases including cancer
Subscribe To Our Newsletter & Stay Updated
